For patients with metastatic melanoma, immunotherapy agents represent a promising treatment option, and researchers are actively seeking to identify factors that may predict a favorable response in patients. Recent studies have elucidated possible associations between the gut microbiome and the effects of immunotherapy, where variations in the gut microbiome may influence treatment response and frequency of adverse effects. In this clinical review, we describe the current literature related to the gut microbiome in the setting of immunotherapy, and we provide an overview of interventions under investigation that may modulate the gut microbiome. These interventions include fecal microbiota transplantation, probiotics, and dietary modifications.
We describe a 69-year-old white man with a recent history of a left forearm sarcoma resection treated with a split-thickness skin graft and radiotherapy who presented with cellulitis of the left forearm, for which a 2-week course of trimethoprim-sulfamethoxazole was prescribed. Ten days into treatment, he presented with flu-like symptoms and a rash. He was eventually diagnosed with Stevens-Johnson syndrome accentuated on the donor split-thickness skin graft on the left thigh region mimicking a recall reaction. There are no other reported cases of Stevens-Johnson syndrome localized within donor graft sites; therefore, this case may represent a novel form of recall reaction.
1 December 2021 in Journal of the American Academy of Dermatology